Compare care options for Panic Disorder

See what we know about each option. We may not have all options. This page does not pick one for you.

Pick up to 4 care options

You can share this page. You do not need an account.

3 selected

What we found

Each option is for Panic Disorder. Research and local care are different facts.

Fluoxetine

What it is

We have not added a short description yet.

Why it is on this page

People: source-defined study populations

DailyMed fluoxetine hydrochloride label · checked Sep 19, 2026

Relationship: label-reported clinical studies for the Need

Scope: country:US

Pointer: /sections/4

Supporting passage: The effectiveness of fluoxetine in the treatment of Panic Disorder was demonstrated in 2 double-blind, randomized, placebo-controlled, multicenter studies of adult outpatients who had a primary diagnosis of Panic Disorder (DSM-IV), with or without agoraphobia.

Open source

Source: DailyMed fluoxetine hydrochloride label. Checked Sep 19, 2026. Scope: country:US. Link: https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/f274f102-67ec-46e7-b248-533be2e3003b.xml

Research for Panic Disorder

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

conclusion

The retained fluoxetine label reports two randomized, placebo-controlled studies for panic disorder; this assessment does not determine personal suitability or compare fluoxetine with every alternative.

DailyMed fluoxetine hydrochloride label · checked Sep 19, 2026

Relationship: supports bounded conclusion

Scope: country:US

Pointer: /sections/4

Supporting passage: The effectiveness of fluoxetine in the treatment of Panic Disorder was demonstrated in 2 double-blind, randomized, placebo-controlled, multicenter studies of adult outpatients who had a primary diagnosis of Panic Disorder (DSM-IV), with or without agoraphobia.

Open source

Source: DailyMed fluoxetine hydrochloride label. Checked Sep 19, 2026. Scope: country:US. Link: https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/f274f102-67ec-46e7-b248-533be2e3003b.xml

Compared with the others: Not directly compared. We show each option’s own research.

See the researchFind care

Cognitive Behavioral Therapy

What it is

We have not added a short description yet.

Why it is on this page

People: source-defined population

NIMH Panic Disorder: What You Need to Know · checked Sep 20, 2026

Relationship: source-described CBT relationship for the Need

Scope: need:panic-disorder

Pointer: /publication/treatmentExcerpt

Open source

Source: NIMH Panic Disorder: What You Need to Know. Checked Sep 20, 2026. Scope: need:panic-disorder. Link: https://www.nimh.nih.gov/health/publications/panic-disorder-when-fear-overwhelms

Research for Panic Disorder

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

conclusion

NIMH describes cognitive behavioral therapy as a research-supported psychotherapy commonly used for panic disorder. This bounded assessment does not compare every option or determine personal suitability.

NIMH Panic Disorder: What You Need to Know · checked Sep 20, 2026

Relationship: supports bounded conclusion

Scope: need:panic-disorder

Pointer: /publication/treatmentExcerpt

Open source

Source: NIMH Panic Disorder: What You Need to Know. Checked Sep 20, 2026. Scope: need:panic-disorder. Link: https://www.nimh.nih.gov/health/publications/panic-disorder-when-fear-overwhelms

Compared with the others: Not directly compared. We show each option’s own research.

See the researchFind care

Sertraline

What it is

We have not added a short description yet.

Why it is on this page

People: source-defined population

DailyMed sertraline (Zoloft) label · checked Sep 20, 2026

Relationship: label-reported clinical studies for the Need

Scope: country:US

Pointer: /sections/2

Supporting passage: The effectiveness of ZOLOFT in the treatment of PD was demonstrated in three double‑blind, placebo‑controlled studies (Studies PD-1, PD-2, and PD‑3) of adult outpatients who had a primary diagnosis of PD (DSM‑III‑R), with or without agoraphobia.

Open source

Source: DailyMed sertraline (Zoloft) label. Checked Sep 20, 2026. Scope: country:US. Link: https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/fda754f6-d0f3-4dce-a17a-927d64f912f7.xml

Research for Panic Disorder

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

conclusion

The current ZOLOFT label reports three double-blind, placebo-controlled studies in adult outpatients with panic disorder. This bounded assessment does not compare every option or determine personal suitability.

DailyMed sertraline (Zoloft) label · checked Sep 20, 2026

Relationship: supports bounded conclusion

Scope: country:US

Pointer: /sections/2

Supporting passage: The effectiveness of ZOLOFT in the treatment of PD was demonstrated in three double‑blind, placebo‑controlled studies (Studies PD-1, PD-2, and PD‑3) of adult outpatients who had a primary diagnosis of PD (DSM‑III‑R), with or without agoraphobia.

Open source

Source: DailyMed sertraline (Zoloft) label. Checked Sep 20, 2026. Scope: country:US. Link: https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/fda754f6-d0f3-4dce-a17a-927d64f912f7.xml

Compared with the others: Not directly compared. We show each option’s own research.

See the researchFind care

Page link: https://everyoption.org/compare/panic-disorder?treatments=fluoxetine%2Ccognitive-behavioral-therapy%2Csertraline